In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anadys Pharmaceuticals Inc.

Division of Roche
www.anadyspharma.com

Latest From Anadys Pharmaceuticals Inc.

Unsuccessful IPOs

Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.

BioPharmaceutical Deals

Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble

Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.

BioPharmaceutical Business Strategies

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.

BioPharmaceutical United States

eFFECTOR Therapeutics raises $45m in Series A

San Diego-based eFFECTOR Therapeutics has raised $45 million in Series A venture capital to develop small molecules that selectively regulate protein synthesis – otherwise known as translation – and advance a cancer drug candidate into human trials within three years.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • ScripTech Pharmaceuticals Inc.
  • Scriptgen Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Steve Worland, PhD, Pres. & CEO
    Peter T Slover, VP, Fin. & Ops.
    James L Freddo, MD, SVP, Drug Dev. & CMO
    Kevin L Eastwood, SVP, Corp. Dev.
  • Contact Info
  • Anadys Pharmaceuticals Inc.
    Phone: (858) 530-3600
    5871 Oberlin Dr.
    Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register